Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Dec 15, 2014; 5(6): 817-834
Published online Dec 15, 2014. doi: 10.4239/wjd.v5.i6.817
Published online Dec 15, 2014. doi: 10.4239/wjd.v5.i6.817
Incretin-based therapies in prediabetes: Current evidence and future perspectives
Georgios S Papaetis, Internal Medicine and Diabetes Clinic, Paphos 8049, Cyprus
Author contributions: Papaetis GS solely contributed to this work.
Correspondence to: Georgios S Papaetis, MD, PhD, Internal Medicine and Diabetes Clinic, Eleftherios Venizelos Avenue 62, Paphos 8049, Cyprus. gpapaetis@yahoo.gr
Telephone: +357-99-273573 Fax: +357-26-220451
Received: August 9, 2014
Revised: September 10, 2014
Accepted: November 7, 2014
Published online: December 15, 2014
Processing time: 126 Days and 0.2 Hours
Revised: September 10, 2014
Accepted: November 7, 2014
Published online: December 15, 2014
Processing time: 126 Days and 0.2 Hours
Core Tip
Core tip: The beneficial effects of incretin-based therapies on β-cell function in patients with type 2 diabetes (T2D) suggested their possible use in individuals with prediabetes, when greater β-cell mass and function are preserved. Both dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists have demonstrated improvements on β-cell function both in preclinical studies and short-term clinical studies. Until future date for their safety are available, large, long term, prevention trials will be required in order to determine whether they can stabilize or reverse β-cell loss and promote a sustained reduction in the development of T2D in this population.